Weekly paclitaxel in patients with recurrent or metastatic head and neck cancer-Reference-Cited by-同舟云学术

Weekly paclitaxel in patients with recurrent or metastatic head and neck cancer

Published:2010-12-24 Issue:3 Volume:68 Page:769-776
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Tahara M.,Minami H.,Hasegawa Y.,Tomita K.,Watanabe A.,Nibu K.,Fujii M.,Onozawa Y.,Kurono Y.,Sagae D.,Seriu T.,Tsukuda M.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-010-1550-3.pdf

Reference36 articles.

1. The Liverpool Head and Neck Oncology Group (1990) A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Br J Cancer 61:311–315

2. Argyriou AA, Chroni E, Koutras A, Ellul J, Papapetropoulos S, Katsoulas G, Iconomou G, Kalofonos HP (2005) Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 64:26–31

3. Brotherton T (2001) Multicenter phase II trial of paclitaxel (taxol) (T): weekly one-hour infusion in previously treated advanced head/neck cancer (AHNC). ASCO, p 231a (abstract 921)

4. Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, Tueni EA, Verweij J, Wildiers J, Clerico M et al (1994) Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 5:521–526

5. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, Kish JA, McClure S, VonFeldt E, Williamson SK et al (1992) Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 10:1245–1251

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody;ESMO Open;2024-06

2. Impact of salvage chemotherapy after immune checkpoint inhibitor for recurrent or metastatic head and neck cancer;Head & Neck;2024-01-16

3. Complete Response to Nivolumab of Resected Adenocarcinoma NOS With Parotid Gland Origin and Lung Metastasis;In Vivo;2022

4. Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma;Cancers;2021-10-30

5. Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients;Frontiers in Oncology;2021-10-27